The use of PARP1 inhibitors associated with NPs has been assayed in some cancers such as hepatocellular carcinoma (arsenite and DOX) [98], prostate cancer (nano-olaparib) [99], ovarian cancer (NPs loaded with olaparib and cisplatin) [100] and, especially, breast cancer. Here, PARP1 is linked to cancer.